<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04143256</url>
  </required_header>
  <id_info>
    <org_study_id>PROT-00109</org_study_id>
    <nct_id>NCT04143256</nct_id>
  </id_info>
  <brief_title>Evaluating Selected Constituents in the Exhaled Breath Samples</brief_title>
  <official_title>An Open-Label, Multi-Center Study to Evaluate Selected Constituents in the Exhaled Breath Samples From the Use of JUUL Nicotine Salt Pod System Product (5% and 3% Virginia Tobacco, Mint, Mango, Menthol) Users and Conventional Cigarettes (Non-Menthol and Menthol Flavors)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Juul Labs, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Juul Labs, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An Open-Label, Multi-Center Study to Evaluate Selected Constituents in the Exhaled Breath
      Samples From the Use of JUUL Nicotine Salt Pod System Product (5% and 3% Virginia Tobacco,
      Mint, Mango, Menthol) Users and Conventional Cigarettes (Non-Menthol and Menthol Flavors)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to evaluate the baseline-adjusted level of selected
      constituents in the exhaled breath sample (EBS) between the two JUUL NSPS products (5% vs 3%
      nicotine by weight) for Virginia Tobacco, Mint, Mango and Menthol flavor and to compare the
      change in absolute level of selected constituents in EBS before and after the use of JUUL
      NSPS (5% and 3% nicotine by weight; Virginia Tobacco, Mint, Mango, Menthol flavors) to the
      change in absolute level of selected constituents before and after the use of menthol and
      non-menthol cigarettes.

      Subjects will be screened for participation in the trial up to 28 days before Day 1. Along
      with screening procedures, all subjects will receive training on EBS collection procedures.
      All subjects will be further trained on the CPS using a training video and site instructions.
      Trained subjects will have the opportunity to try the JUUL NSPS.

      Eligible subjects will be scheduled for a Day 1 clinic visit. Within 24 to 48 hours prior to
      Check-in, the clinic staff will provide a courtesy phone call to subjects to remind them to
      abstain from the use of alcohol, any nicotine-containing products and mint/mentholated
      products for at least 12 hours prior and xanthines/caffeine for at least 24 hours prior to
      screening and Day 1.

      Following completion of the check-in events, including re-instruction on the EBS sample
      collection technique and CPS instructions, subjects will participate in the exhaled breath
      collection test sessions.

      Groups I - IV will complete two periods of baseline and test sample collections with a 3-hour
      break in between each period. Each period will consist of two baseline samples (the first for
      analysis of nicotine, propylene glycol and glycerin and the second for analysis of
      acetaldehyde, acrolein, benzoic acid, formaldehyde, and menthol), followed by product use,
      and then two test samples (similar to baseline). Exhaled CO will be measured before the first
      baseline sample, after the second baseline sample, before the first test sample and after the
      second test sample. Pods used during the test sessions will be weighed before and after use.

      Groups V and VI will complete only one period of baseline and test sample collections,
      consisting of two baseline sample collections and two test sample collections similar to that
      noted above.

      A follow-up phone call with subjects will be made the day after Check-out (or early
      withdrawal). Provided there are no adverse events which require further attention, the
      subject's participation in the trial will be complete.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 3, 2019</start_date>
  <completion_date type="Actual">December 13, 2019</completion_date>
  <primary_completion_date type="Actual">December 12, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Four crossover groups and two single arm groups</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate Absolute Change from Baseline Level</measure>
    <time_frame>Up to 6-hours</time_frame>
    <description>The absolute change from baseline level of nicotine for each subject.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate Absolute Change from Baseline Level</measure>
    <time_frame>Up to 6-hours</time_frame>
    <description>The absolute change from baseline level of propylene glycol for each subject.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate Absolute Change from Baseline Level</measure>
    <time_frame>Up to 6-hours</time_frame>
    <description>The absolute change from baseline level of vegetable glycerin for each subject.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate Absolute Change from Baseline Level</measure>
    <time_frame>Up to 6-hours</time_frame>
    <description>The absolute change from baseline level of acetaldehyde for each subject.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate Absolute Change from Baseline Level</measure>
    <time_frame>Up to 6-hours</time_frame>
    <description>The absolute change from baseline level of acrolein for each subject.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate Absolute Change from Baseline Level</measure>
    <time_frame>Up to 6-hours</time_frame>
    <description>The absolute change from baseline level of benzoic acid for each subject.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate Absolute Change from Baseline Level</measure>
    <time_frame>Up to 6-hours</time_frame>
    <description>The absolute change from baseline level of formaldehyde for each subject.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate Absolute Change from Baseline Level</measure>
    <time_frame>Up to 6-hours</time_frame>
    <description>The absolute change from baseline level of menthol for each subject.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate Absolute Change from Baseline Level</measure>
    <time_frame>Up to 6-hours</time_frame>
    <description>The absolute change from baseline level of carbon monoxide for each subject.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare the change between baseline and post-baseline levels</measure>
    <time_frame>Up to 6-hours</time_frame>
    <description>Compare the change between baseline and post-baseline levels of nicotine for each subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the change between baseline and post-baseline levels</measure>
    <time_frame>Up to 6-hours</time_frame>
    <description>Compare the change between baseline and post-baseline levels of propylene glycol for each subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the change between baseline and post-baseline levels</measure>
    <time_frame>Up to 6-hours</time_frame>
    <description>Compare the change between baseline and post-baseline levels of vegetable glycerin for each subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the change between baseline and post-baseline levels</measure>
    <time_frame>Up to 6-hours</time_frame>
    <description>Compare the change between baseline and post-baseline levels of acetaldehyde for each subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the change between baseline and post-baseline levels</measure>
    <time_frame>Up to 6-hours</time_frame>
    <description>Compare the change between baseline and post-baseline levels of acrolein for each subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the change between baseline and post-baseline levels</measure>
    <time_frame>Up to 6-hours</time_frame>
    <description>Compare the change between baseline and post-baseline levels of benzoic acid for each subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the change between baseline and post-baseline levels</measure>
    <time_frame>Up to 6-hours</time_frame>
    <description>Compare the change between baseline and post-baseline levels of formaldehyde for each subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the change between baseline and post-baseline levels</measure>
    <time_frame>Up to 6-hours</time_frame>
    <description>Compare the change between baseline and post-baseline levels of menthol for each subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the change between baseline and post-baseline levels</measure>
    <time_frame>Up to 6-hours</time_frame>
    <description>Compare the change between baseline and post-baseline levels of carbon monoxide for each subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in weight</measure>
    <time_frame>Up to 45</time_frame>
    <description>Change in the weight of JUUL pods before and after the usage.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">135</enrollment>
  <condition>Electronic Cigarette Use</condition>
  <condition>Cigarette Use, Electronic</condition>
  <condition>Tobacco Use</condition>
  <condition>Tobacco Smoking</condition>
  <arm_group>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with ENDS user history may be randomized to use JUUL ENDS 5% Virginia Tobacco and 3% Virginia Tobacco</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with ENDS user history may be randomized to use JUUL ENDS 5% Mint and 3% Mint</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with ENDS user history may be randomized to use JUUL ENDS 5% Menthol and 3% Menthol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with ENDS user history may be randomized to use JUUL ENDS 5% Mango and 3% Mango</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group V</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with cigarette user history will be assigned to use US Cigarette, Non-Menthol Flavor (Marlboro Gold King Size)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group VI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with cigarette user history will be assigned to use US Cigarette, Menthol Flavor (Newport King Size)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>JUUL ENDS 5% Virginia Tobacco</intervention_name>
    <description>JUUL ENDS Virginia Tobacco 5% nicotine strength</description>
    <arm_group_label>Group I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>JUUL 3% Virginia Tobacco ENDS</intervention_name>
    <description>JUUL ENDS Virginia Tobacco 3% nicotine strength</description>
    <arm_group_label>Group I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>JUUL 5% Mint ENDS</intervention_name>
    <description>JUUL ENDS Mint 5% nicotine strength</description>
    <arm_group_label>Group II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>JUUL 3% Mint ENDS</intervention_name>
    <description>JUUL ENDS Mint 3% nicotine strength</description>
    <arm_group_label>Group II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>JUUL 5% Menthol ENDS</intervention_name>
    <description>JUUL ENDS Menthol 5% nicotine strength</description>
    <arm_group_label>Group III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>JUUL 3% Menthol ENDS</intervention_name>
    <description>JUUL ENDS Menthol 3% nicotine strength</description>
    <arm_group_label>Group III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>JUUL 5% Mango ENDS</intervention_name>
    <description>JUUL ENDS Mango 5% nicotine strength</description>
    <arm_group_label>Group IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>JUUL 3% Mango ENDS</intervention_name>
    <description>JUUL ENDS Mango 3% nicotine strength</description>
    <arm_group_label>Group IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>US Cigarette, Non-menthol - Marlboro Gold King Size</intervention_name>
    <description>US Cigarette, Non-menthol - Marlboro Gold King Size</description>
    <arm_group_label>Group V</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>US Cigarette, Menthol - Newport King Size</intervention_name>
    <description>US Cigarette, Menthol - Newport King Size</description>
    <arm_group_label>Group VI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Be a healthy male or female aged 21 - 65 years, inclusive, at the time of signing the
             informed consent.

          2. Be informed of the nature of the study, agree to and are able to read, review, and
             sign the informed consent document prior to any study procedures. The informed consent
             document will only be available in English. Therefore, the volunteer must have the
             ability to read and communicate in English in order to participate in the study.

          3. Complete the screening process up to 28 days prior to Day 1.

          4. Satisfy the user definitions of either cigarette user or ENDS/closed system user.

          5. Agree to abide by the study restrictions.

          6. Agree to abstain from use of alcohol 12 hours before the start of Day 1 for Groups I
             through VI.

          7. Agree to abstain from use of any nicotine products 12 hours before the start of study
             day 1 for Groups I through VI.

          8. Agree to not consume any mint or menthol flavor products (e.g., chewing gum, mouth
             wash, toothpaste, etc.) 12 hours before the start of testing for Groups I through VI.

          9. Have a positive urine cotinine result at screening of &gt;200 ng/ml.

         10. A female subject of childbearing potential must have been using one (1) of the
             following forms of contraception and agree to continue using it through completion of
             the trial:

               -  hormonal (e.g., oral, vaginal ring, transdermal patch, implant, or injection)
                  consistently for at least 3 months prior to Day 1;

               -  double barrier method (e.g., condom with spermicide, diaphragm with spermicide)
                  at screening.

               -  intrauterine device for at least 3 months prior to Day 1;

               -  a partner who has been vasectomized for at least 6 months prior to Day 1;

               -  abstinence beginning at least 6 months prior to screening.

         11. A female subject of non childbearing potential must have undergone one of the
             following sterilization procedures at least 6 months prior to Day 1:

               -  hysteroscopic sterilization;

               -  bilateral tubal ligation or bilateral salpingectomy;

               -  hysterectomy;

               -  bilateral oophorectomy;

               -  Or be postmenopausal with amenorrhea for at least 1 year prior to Day 1.

         12. Be judged by the Investigator to be in good general health as documented by the
             medical history, physical examination (including but may not be limited to an
             evaluation of the cardiovascular, gastrointestinal, respiratory and central nervous
             systems), vital sign assessments and by general observations. Any abnormalities or
             deviations outside the normal ranges for any clinical testing (e.g. vital signs) can
             be repeated at the discretion of the Investigator and judged to be not clinically
             significant for study participation.

        Exclusion Criteria:

          1. Report receiving any investigational product, participated in any previous clinical
             study for an investigational drug, device, biologic, or tobacco product within 30 days
             prior to screening.

          2. Report at screening using both ENDS and conventional cigarettes (menthol or
             non-menthol) (dual users), or use of other inhaled products (such as, but not limited
             to cannabis) in the past 3 months.

          3. For ENDS users, be unable to perform CPS or incapable of drawing down the pod weight
             by 20-60mg after 3 attempts at screening.

          4. If female, be pregnant, have a positive urine pregnancy test at screening, be
             lactating, breast feeding, or intend to become pregnant during the time period from
             screening through the end of the study.

          5. Have any clinically significant results from physical examinations and vital signs
             assessments, as judged by the Investigator.

          6. Have a systolic blood pressure &lt; 90 mmHg or &gt; 150 mmHg, diastolic blood pressure &lt; 40
             mmHg or &gt; 95 mmHg, or heart rate &lt; 40 bpm or &gt; 99 bpm at screening.

          7. Report a clinically significant illness during the 30 days prior to enrollment, as
             determined by the Investigator.

          8. Report a history of drug or alcohol addiction or abuse within the past 1 year.

          9. Have a positive screen for alcohol or drugs of abuse at screening or at check-in on
             Day 1.

         10. Have a body mass index (BMI) greater than 40 kg/m2 or less than 18 kg/m2 at screening.

         11. Have used prescription anti-diabetic medication and/or insulin therapy within 12
             months of screening.

         12. Have taken medication for depression, asthma, or chronic obstructive pulmonary disease
             within 6 months of screening.

         13. Have used prescription or over-the-counter bronchodilator medication (e.g., inhaled or
             oral Î²-agonists) within 6 months of screening.

         14. Be breast-feeding or pregnant female subjects (confirmed by a positive pregnancy
             test). Female subjects, who are considered women of child bearing potential (WOCBP)
             and sexually active, must be willing and able to use an acceptable method of
             contraception from screening through the end of the study.

         15. Have experienced an allergic reaction following previous e-cigarette use or with
             exposure to any primary components of the e-liquids (nicotine, flavor, benzoic acid,
             propylene glycol, and/or glycerol.

         16. Be or have a first-degree relative (i.e. parent, sibling or child) who is a current
             employee of CRO, Sponsor, or site.

         17. In the opinion of an Investigator, be deemed not eligible to participate in this
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Frontage Clinical Services</name>
      <address>
        <city>Secaucus</city>
        <state>New Jersey</state>
        <zip>07094</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rose Research Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rose Research Center</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 24, 2019</study_first_submitted>
  <study_first_submitted_qc>October 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2019</study_first_posted>
  <last_update_submitted>February 10, 2020</last_update_submitted>
  <last_update_submitted_qc>February 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Electronic Nicotine Delivery</keyword>
  <keyword>Combustible Cigarettes</keyword>
  <keyword>Nicotine</keyword>
  <keyword>Exhaled Breath</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Menthol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to share IPD to other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

